Hasil Pencarian  ::  Simpan CSV :: Kembali

"ABSTRAK

Securities Investor Protection Fund merupakan hal yang baru dalam kegiatan pasar modal di Indonesia dibanding dengan di negara lain seperti Amerika Serikat dan Singapura. Lembaga ini memberikan ganti kerugian terhadap investor yang mengalami kerugian akibat kesalahan perusahaan efek. Implementasi Dana Perlindungan Pemodal di pasar modal Indonesia diharapkan dapat meningkatkan kepercayaan pemodal dan juga menambah jumlah pemodal. Dalam tulisan ini akan dibahas mengenai implementasi lembaga Securities Investor Protection Fund di Indonesia serta perbandingan penerapannya di negara lain seperti Amerika Serikat dan Singapura guna mengetahui ketersesuain penerapan Securities Investor Protection Fund di Indonesia dibanding dengan penerapannya di negara lain.

---

ABSTRACT

Securities Investor Protection Fund organization is a recent organization in Indonesia compared to other countries, such as United States of America and Singapore. This organization will provide indemnification to an investor who suffers loss due to the failure of securities company. Implementation of Securities Investor Protection Fund organization is expected to increase investor’s trust and number of the investor. This thesis will discuss implementation of Securities Investor Protection Fund organization in Indonesia compared to the implementation of the similar organization in United States of America and Singapore in order to obtain understanding on the conformity of the implementation within the countries.

"

"The pharmaceutical industry is praised as a leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. Yet the industry is also reviled for its marketing and pricing practices and even its research and development priorities. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This second edition includes six new chapters on emerging topics such as the broadened role of FDA regulations, alternative drugs or "nutraceuticals," and biotechnology and other industries related to pharmaceuticals. Existing chapters are fully revised and updated to include new materials. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care. "